Zymeworks and ALX Oncology Collaborate to Evaluate Zanidatamab + ALX148 for Advanced HER2‑Expressing Breast Cancer

 Zymeworks and ALX Oncology Collaborate to Evaluate Zanidatamab + ALX148 for Advanced HER2‑Expressing Breast Cancer

Zymeworks and ALX Oncology Collaborate to Evaluate Zanidatamab + ALX148 for Advanced HER2‑Expressing Breast Cancer

Shots:

  • Zymeworks will conduct a P-Ib study to assess the safety and efficacy of the combination of zanidatamab and ALX148 in a two-part study
  • The 1st part will evaluate the safety of the combination regimen while the 2nd part will assess the safety, tolerability, and anti-tumor activity in separate cohorts of subjects with HER2+ BC, HER2-low BC, and non-breast HER2-expressing solid tumors
  • Zanidatamab is in the advanced clinical stage, actively enrolling a study in patients with prior treated HER2 gene-amplified BTC while five active P-II programs are underway. ALX148 is a next-generation CD47 blocker and has the potential to expand the chance for zanidatamab to benefits patients with HER2‑expressing BC

Click here ­to­ read full press release/ article | Ref: Zymeworks | Image: Medium

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post